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Abstract
Objective—Consider all metabolic syndrome (MetS) components [systolic (SBP) and diastolic 
(DBP) blood pressures, waist circumference, HDL cholesterol, triglycerides (TG), and fasting 
glucose] and gender/race differential risk when assessing cardiovascular disease (CVD) risk.
Methods—We estimated a gender- and race-specific continuous MetS score using structural 
equation modeling and tested its association with CVD mortality using data from National Health 
and Nutrition Examination Survey III linked with the National Death Index. Cox proportional 
hazard regression tested the association adjusted for sociodemographic and behavior 
characteristics.
Results—For men, continuous MetS components associated with CVD mortality were SBP 
(hazard ratio =1.50, 95% confidence interval =1.14–1.96), DBP (1.48, 1.16–1.90), and TG (1.15, 
1.12–1.16). In women, SBP (1.44, 1.27–1.63) and DBP (1.24, 1.02–1.51) were associated with 
CVD mortality. MetS score was not significantly associated with CVD mortality in men; but 
significant associations were found for all women (1.34, 1.06–1.68), non-Hispanic white women 
(1.29, 1.01–1.64), non-Hispanic black women (2.03, 1.12–3.69), and Mexican-American women 
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(3.57, 2.21–5.76). Goodness-of-fit and concordance were overall better for models with the MetS 
score than MetS (yes/no).
Conclusions—When assessing CVD mortality risk, MetS score provided additional information 
than MetS (yes/no).
Introduction
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide (1). A 
cluster of risk factors commonly found among individuals with CVD (dyslipidemia, 
hypertension, hyperglycemia, and excess abdominal fat) led to the development of a 
condition known as metabolic syndrome (MetS) (2). Most recently, a harmonized MetS 
definition was presented as having abnormal values for three of the five metabolic 
components: blood pressure, fasting glucose, waist circumference, HDL cholesterol, or 
triglycerides (3), based on established cut points.
Although MetS predicts CVD events (4,5), there are some major limitations to the most 
recent harmonized definition of MetS (3). First, the established cut points of each metabolic 
component may not be most effective in predicting CVD risk for certain subgroups or 
populations. One example is the MetS paradox among African-Americans who have greater 
prevalence of hypertension and better cholesterol profiles than other races/ethnicities (6,7), 
and cut points may need to be adapted to identify early CVD risk. Additionally, the current 
MetS definition does not distinguish between which components are present, and there may 
be interaction between combinations of components that result in greater CVD risk than 
others. Additional limitations raised by a joint statement from the American Diabetes 
Association and the European Association for the Study of Diabetes includes ill-defined cut 
points with possible loss of information, lack of basis for the inclusion or exclusion of other 
CVD risk factors, and treatment of MetS is no different than the treatment of its components 
(8). Overall, the medical value of diagnosing MetS was questioned. However, CVD events 
and mortality have been found to be driven by MetS independently from the components (9). 
Additionally, individuals with MetS are at increased risk of CVD mortality and all-cause 
mortality compared with those without MetS (10–13). Even though these studies have 
consistently found a positive relationship between MetS and CVD mortality, MetS is 
criticized due to limitations of the definition (yes/no) and the inflexibility of evaluating 
abnormal MetS components differently for race and gender subgroups.
Even though the harmonized definition has provided country- and gender-specific cut points 
for a couple of components, ideally we would use the measured value of each component 
when assessing CVD risk while acknowledging differential risk among certain populations. 
In this study, we tested independent associations between each metabolic component and 
CVD mortality. Then, we used a method that addresses the limitations of MetS by 
estimating an individual continuous MetS score based on the actual value of all components 
and tested its association with CVD mortality.
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Methods
Study population
Data from the National Health and Nutrition Examination Survey III (NHANES III) was 
used where participants were selected from a complex, multistage, probability sampling 
design to represent the non-institutionalized US population (14). NHANES III was 
conducted from 1988 to 1994 and contains data on 19,288 nonpregnant adults aged 18 years 
or older. Data on participants from NHANES III were linked to death certificates from the 
National Death Index to obtain mortality status through December 31, 2006 (15). CVD 
mortality was classified as cause of death from Major Cardiovascular Diseases or ICD-10 
codes of I00 to I78.
Of the 19,288 nonpregnant adults, 25 were ineligible for mortality linkage resulting in a 
remaining 19,263 participants. Participants were then excluded if there were: no fasting lab 
data available (n = 11,157); no measurements for blood pressure (n = 2345) or 
anthropometric (n = 3154); medical history of cancer (n = 775), heart failure (n = 747), 
stroke (n = 646), or heart attack (n = 932); or missing covariate data (n = 772). These 
numbers are not mutually exclusive and 5759 participants remained in this study. Morning 
sample weights, also known as fasting weights, were used to account for non-response due 
to not fasting or missing laboratory data.
Measurements
Participants underwent interviews and detailed physical exams. Waist circumference was 
measured to the nearest 0.1 cm from the top of the iliac crest with the tape measure parallel 
to the floor. Blood pressure was determined based on an average of three blood pressure 
measurements. Blood samples were collected to obtain measures of plasma glucose and lipid 
profiles (HDL cholesterol and triglycerides).
MetS was based on the latest harmonized definition of having three or more abnormal values 
of any of the following components: blood pressure, fasting glucose, waist circumference, 
HDL cholesterol, and triglycerides (3). Presence of the blood pressure component was a 
systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or prescribed 
medication use for high blood pressure. Abnormal fasting glucose was defined as ≥100 
mg/dl or the use of glucose altering medication (insulin/diabetic pills). Gender-specific cut 
points were specified for waist circumference (men: ≥102 cm and women: ≥88 cm) and 
HDL cholesterol components (men: <40 mg/dl and women: <50 mg/dl). Abnormal 
triglycerides were ≥150 mg/dl. Participants meeting three or more of these criteria were 
categorized as having MetS.
Statistical analysis
All analyses used sampling weights and adjusted variance estimates to account for the 
complex sampling design. Demographic characteristics were described as count and percent 
for discrete variable and mean with standard errors for continuous variables. Structural 
equation modeling, a statistical estimation method, was used to calculate a metabolic score 
for each participant based on the values of the following metabolic components: systolic 
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blood pressure, diastolic blood pressure, fasting glucose, waist circumference, HDL 
cholesterol, and triglycerides. During the estimation process, correlated errors were specified 
between systolic and diastolic blood pressure measures as well as between HDL cholesterol 
and triglycerides due to the relationship these variables have with each other. For the 
purpose of comparing components’ contribution to the metabolic score, factor loadings were 
standardized based on the variance of the fitted model. Because gender and race/ethnic 
differences in the distribution of some of these components may exist, path diagrams were 
estimated separately for each gender-race subgroup, and differences were tested using Score 
and Wald tests. Goodness-of-fit of the specified path diagrams were assessed by the 
standardized root mean squared residuals (SRMR; good fit ≤0.08) and by the coefficient of 
determination (CD; good fit >0.56 which is equivalent to an R2 of 0.75).
Cox proportional hazards regression analysis was used to test the association between time 
to CVD death in five ways: (1) each continuous metabolic component independently, (2) 
harmonized MetS (yes/no), (3) the number of metabolic components present based on 
harmonized cut points and (4) the metabolic score calculated from structural equation 
modeling. When testing the independent association between CVD mortality and each 
metabolic component, components were standardized to have a distribution of mean zero 
and a standard deviation of one for the purpose of coefficient comparison across models. 
Meaning, the greatest coefficient with significance would be considered a more important 
predictor. Person-time used in these analyses was the date from the NHANES in-person 
exam to the day of death or December 31, 2006 for those assumed alive. Since metabolic 
scores are gender and race specific, hazard ratios were stratified by gender and race/
ethnicity. Models were adjusted for: age (years), education (highest grade or year of school 
completed), physical activity [active (moderated physical activity ≥5 times per week or 
vigorous physical activity ≥3 times per week) or inactive], smoking status (never, former, or 
current), alcohol consumption (none, less than three drinks per week, or three or more per 
week), and self-reported medication use for hypertension, diabetes, or high cholesterol. 
Statistical significance was denoted as P value less than 0.05.
Comparison between models using the harmonized MetS definition, number of abnormal 
components, and metabolic score were based on predictability of the models from 
concordance analysis (Harrell’s C coefficient and Gonen and Heller’s K coefficient) and 
goodness-of-fit (Akaike Information Criterion, Bayesian Information Criterion, and 
Royston’s R2). These models were also tested against a model having all the MetS 
components in the model as continuous variables. All analyses were performed using 
STATA 13.0 (StataCorp LP, College Station, TX).
Results
Demographic, anthropometric, and laboratory characteristic by gender and race/ethnicity are 
presented in Table 1. Women had an older age distribution than men with 15% being 65 
years or older compared with 11% of men. Mexican-Americans were a younger group with 
76% between the ages of 18 and 44 years compared with African-Americans (69%) and 
non-Hispanic whites (57%). About 47% of men and 43% of women had some college 
education or college degree. Education varied between race/ethnic groups with 18% of 
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Mexican-Americans, 34% of African-Americans, and 48% of non-Hispanic whites with 
some college education or college degree attainment. The prevalence of MetS did not greatly 
vary by gender, but there was some variability among race/ethnic groups with 22% of non-
Hispanic blacks meeting harmonized MetS compared with 28% non-Hispanic whites and 
31% of Mexican-Americans. Person-time of follow-up was similar between gender and race/
ethnic groups.
Systolic blood pressure, diastolic blood pressure and triglycerides were independently 
associated with CVD mortality in non-Hispanic white men (Table 2). In these associations, 
the strength of association was greatest for systolic blood pressure (adjusted standardized 
hazard ratio =1.51, 95% confidence interval: 1.06–2.16) and diastolic blood pressure (1.51, 
1.10–2.07) compared with triglycerides (1.16, 1.13–1.19). Among non-Hispanic black men, 
systolic (1.58, 1.17–2.13) and diastolic (1.53, 1.21–1.93) blood pressures as well as HDL 
cholesterol (1.43, 1.14–1.79) were independently associated with CVD mortality. None of 
the metabolic components were independently associated with CVD mortality among 
Mexican-American men.
Systolic blood pressure was associated with CVD mortality within all race/ethnic groups in 
women and the strongest association was observed among Mexican-American (1.97, 1.20–
3.23) compared with non-Hispanic whites (1.43, 1.22–1.68) and non-Hispanic blacks (1.44, 
1.18–1.75) (Table 2, unadjusted estimates Supporting Information Table S1). Diastolic blood 
pressure was associated with CVD mortality among all women (1.24, 1.02–1.51). Other 
significant independent association with CVD mortality was fasting glucose (1.68, 1.40–
2.01) in Mexican-American women.
There was slight variation in the standardized factor loadings from the structural equation 
modeling by gender and race/ethnicity (Figure 1). Based on the Score and Wald tests 
(Supporting Information Table S2), factor loadings in the path diagrams were significantly 
different across gender and race groups. Overall, the standardized factor loadings were 
greatest for waist circumference (ranging from 0.58 to 0.81) for all subgroups. In men, 
standardized factor loading absolute values for all other metabolic components were close to 
half that of waist circumference, with HDL having a negative value. The greatest variation in 
factor loadings across race/ethnic groups in men was between systolic (ranging from 0.34 to 
0.43) and diastolic (ranging from 0.25 to 0.57) blood pressures. In women, standardized 
factor loadings for metabolic components varied more across race/ethnic groups compared 
with men with the largest range observed for waist circumference (0.58–0.80). Standardized 
factor loadings estimated without correlated errors for SBP and DBP as well as HDL and 
TG are shown on Supporting Information Figure S1. Since estimated covariance between 
SBP and DBP as well as HDL and TG were significantly different than zero (P value <0.05, 
and in most cases P value <0.001), all further results only considered MetS score derived 
from the path diagrams with specified correlated error. Based on the SRMR and CD, all path 
diagrams had good fit.
The metabolic score derived from the structural equation modeling was associated with 
CVD mortality for: non-Hispanic white women (1.29, 1.01–1.64), non-Hispanic black 
women (2.03, 1.12–3.69), and Mexican-American women (3.57, 2.21–5.76) (Table 3, 
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unadjusted estimates Supporting Information Table S3). In this study, the harmonized 
defined MetS (yes/no) was not significantly associated with CVD mortality in almost all of 
the gender and race/ethnic subgroups with the exception among non-Hispanic black women 
(2.69, 1.45–4.97). The number of abnormal metabolic components present based on the 
harmonized definition was associated with CVD mortality for: non-Hispanic white women 
(1.15, 1.04–1.27), non-Hispanic black women (1.40, 1.10–1.77), and Mexican-American 
women (1.32, 1.07–1.61). When comparing the models using the metabolic score with those 
using harmonized MetS or the number of abnormal metabolic components present, the 
models with the metabolic score were a better fit based on the Akaike Information Criterion 
and Bayesian Information Criterion. Using concordance analysis, for the most part, the 
models with better predictability were those with the metabolic score based on the Harrell’s 
C coefficient and Gönen and Heller’s K coefficient (Supporting Information Table S4). 
However, having all metabolic components as continuous variables in the model had the best 
fit.
Discussion
SEM to examine the associations between MetS and cardiovascular mortality has been 
sparsely utilized, yet it offers some advantages in assessing risk including considering actual 
values for each MetS component, their collective association with cardiovascular risk, and 
allowing the collective influence of MetS components to vary within subgroups of race/
ethnicity and gender. MetS conceptually has been an information reduction approach in 
identifying those individuals at greater risk for CVD mortality instead of considering all 
components as predictors which resulted in the best fit and predictability model (Supporting 
Information Table S4). However, among the three forms of defining metabolic syndrome, 
the metabolic score estimated from SEM was a slightly better predictor for CVD mortality 
compared with harmonized MetS or the number of metabolic components present in this 
study of a representative sample of US adults.
Of all the metabolic components, systolic and diastolic blood pressure measures were 
repeatedly independently associated with CVD mortality across gender and race/ethnicity 
subgroups. Even though systolic blood pressure and diastolic blood pressure were associated 
with CVD mortality in this study, it is an association previously documented in other studies 
(16–18). Although it has been previously recognized that waist circumference (19–21), 
triglycerides (22), and fasting glucose (23) are independently associated with CVD risk; 
these findings were not consistent in this study. There were no significant associations 
observed with waist circumference and CVD mortality. Several significant linear 
associations with CVD mortality were observed within selected groups, including: fasting 
glucose among Mexican-American women, triglycerides among non-Hispanic white men, 
HDL cholesterol among non-Hispanic black men, and blood pressure among all groups 
except Mexican-American men. Dichotomizing these variables, as what is done in the 
harmonized MetS, may lose the effectiveness of quantifying CVD risk.
Many studies have found MetS to be associated with CVD events and/or mortality (13,24–
32). Even though this association was not observed in this study, some reasons for the 
discrepancy could be due to the MetS definition used and the study population. Before the 
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release of the harmonized definition in 2009, all MetS studies varied on the components and 
cut points used to define MetS relying on definitions from the World Health Organization, 
European Group for the Study of Insulin Resistance, National Cholesterol Education 
Program, American College of Endocrinology, or International Diabetes Federation. 
Although systematic reviews and meta-analyses on this topic have been consistent showing a 
positive association between MetS and CVD (13,24–26,28,32), the findings between studies 
were variable and the harmonized definition used in this study has been reported to attenuate 
results more so than the other definitions (11,12,27). Furthermore, some studies would 
substitute certain measures for others based on the data collected, such as using body mass 
index as opposed to waist circumference. In addition, the majority of the studies that 
investigated the association between MetS and CVD events or mortality were conducted 
among populations outside of the US. The few studies from the US were not very diverse or 
did not report results within gender or race/ethnic subgroups.
A major weakness of all the MetS definitions is that quantifying CVD risk is limited to 
yes/no and differentiation of CVD risk between combinations of components is ignored. 
Components may not weigh equally towards CVD risk and different clusters of components 
may increase CVD risk more so than others (27,31). In a study by Huang et al. (27), the 
cluster of high blood pressure, HDL, and WC appeared to have the highest risk for CVD 
mortality of all combinations, even compared with having all metabolic components present. 
They also observed that having high blood pressure, HDL, WC, and FG decreased the risk 
by half compared with if FG was not in the cluster. The underlying etiology of how the 
components interact to increase CVD risk is unknown. We do not fully understand the 
relationship all metabolic components have in relation to CVD risk and two-way, three-way, 
four-way, or a five-way interaction between metabolic components may be present. As a 
result, using harmonized MetS or treating metabolic components individually may not be the 
most effective way to assess or address CVD risk, especially among certain subgroups or 
populations.
Previous studies using SEM to assess MetS with CVD risk have found positive associations 
with atherosclerosis, coronary artery calcification, diabetes, carotid intima media thickness, 
and CVD mortality (33–37). Although gender and race/ethnicity subgroup differences in 
MetS using SEM has been noted (34,38,39); the previous studies either did not consider 
these differences, examined different path diagrams, or had study populations from other 
countries compared with this study. However, across all studies, the consensus was that 
assessing MetS using SEM was more effective in estimating CVD risk than MetS (yes/no).
There are a few limitations in this study. First, the follow-up time is based on linkage to 
death certificates from the National Death Index and it is possible that some deaths might 
have been missed. Second, we were unable to capture CVD events; we only had data on 
CVD mortality which limits our ability to assess the association with MetS and overall CVD 
risk. Third, the structural equation model proposed may not represent the true underlying 
etiology, especially if there are interactions between components. We considered each 
metabolic component acting independently although simultaneously in contributing to the 
metabolic score, but we may need to consider how the values of some components may 
affect the values of another to further increase CVD risk. Additionally, the structural 
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equation model assumed a reflective approach implying that changes in the latent variable, 
MetS score, affect each component as opposed to the counterfactual formative approach 
inferring that changes in the components affect the MetS score. Potential mis-specification 
of the model approach can be problematic in determining which components load on a 
factor when performing traditional factor analysis (40). However, in our study we did not 
conduct any exploratory analysis to determine which variables to include as components of 
the MetS score but tested a pre-specified structural equation model based on predetermined 
risk factors and therefore potential mis-specification of the model would not affect our 
results. Fourth, although we were able to link to mortality data, all measured data were of 
cross-sectional design and only obtained at baseline. Therefore, changes may have occurred 
during follow-up time that changed CVD risk; such as initiation of medication use, 
diagnosis, or medical procedures; could not be accounted for in this study. Fifth, many 
statistical tests were performed and some significant results may have occurred due to 
chance. Finally, significant differences in the SEM analyses may have been a function of 
large sample sizes.
Future studies are needed to understand the etiology of metabolic components and how they 
may interact or relate to CVD risk. Although studies have shown CVD risk differences by 
gender and by race, most studies do not show results within race-gender subcategories and 
there is a need for more research in this area. Another research focus needed is 
investigations within subcategories of CVD due to the heterogeneity of this category (e.g., 
stroke, heart attack, or arrhythmia). Risk assessment using harmonized MetS may not 
capture or distinguish risk severity for CVD mortality. Although it has been previously 
stated that treatment for MetS is no different than the treatment of each component (8) and it 
may be the best current approach, treating individual risk factors independently may not be 
the most effective treatment method due to possible interactions between components which 
may require consideration of the relationship these factors have with each other. Other than 
diet and physical activity which may affect all components, we recognize that at this time 
treating each component individually and focusing on prevention are the best practices 
available until more is learned and the knowledge gap is narrowed. In this study, SEM to 
assess CVD mortality risk provided additional information than harmonized MetS or the 
number of MetS components present in that predictions became significant when using the 
metabolic score. Although the metabolic score driven from SEM has the potential to 
accurately estimate CVD risk tailored for different subgroups and therefore have positive 
clinical and public health implications, at this time more knowledge is needed on the 
etiology between metabolic components and CVD risk to establish the true path diagram and 
may be the reason that the models with all the components present predicted CVD mortality 
better than any of the MetS approaches. Even though calculations of the metabolic score 
using SEM is complex posing impractical risk assessment ability in the clinical setting, the 
future of electronic medical records may be able to take the actual metabolic component 
values and estimate more accurate CVD risk tailored for certain subgroups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Metabolic score path diagrams with standardized factor loadings for each gender-race 
subgroup among US adults—National Health and Nutrition Examination Survey III, 1988–
2006. WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HDL, high-density lipoprotein; TG, triglycerides; FG, fasting glucose.
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